Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Schultz

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and CeritinibJustin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
American Journal of Infection Control|August 20, 2021
Building a personal protective equipment monitor team as part of a comprehensive COVID-19 prevention strategyShelley Summerlin-Long, Amy Selimos, Brooke Brewer, et al.
Journal of Clinical Microbiology|July 13, 2018
Preventable Patient Harm: a Multidisciplinary, Bundled Approach to Reducing Clostridium difficile Infections While Using a Glutamate Dehydrogenase/Toxin Immunochromatographic Assay/Nucleic Acid Amplification Test Diagnostic AlgorithmKatherine Schultz, Emily Sickbert-Bennett, Ashley Marx, et al.
Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and CeritinibJustin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
American Journal of Infection Control|August 20, 2021
Building a personal protective equipment monitor team as part of a comprehensive COVID-19 prevention strategyShelley Summerlin-Long, Amy Selimos, Brooke Brewer, et al.
Journal of Clinical Microbiology|July 13, 2018
Preventable Patient Harm: a Multidisciplinary, Bundled Approach to Reducing Clostridium difficile Infections While Using a Glutamate Dehydrogenase/Toxin Immunochromatographic Assay/Nucleic Acid Amplification Test Diagnostic AlgorithmKatherine Schultz, Emily Sickbert-Bennett, Ashley Marx, et al.
Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.
Pageof 2